AstraZeneca (AZN) will launch a cholesterol-lowering drug later this year to compete with Pfizer's $6.4 billion Lipitor. And new treatments for erectile dysfunction could hurt $1.5 billion Viagra.
DWINDLING COST SAVINGS
It will be hard to top the $1.4 billion savings Pfizer (PFE) achieved in 2001, or the $300 million it expects to save this year, after its acquisition of Warner-Lambert.
FEW BIG NEW PRODUCTS
Pfizer has some possible blockbusters coming, such as pregabalin, which treats epilepsy and neuropathic pain. But an eagerly anticipated inhaled insulin drug has been delayed at least a year.